Nirsevimab Effectiveness Against Intensive Care Unit Admission for Respiratory Syncytial Virus in Infants – 24 States, December 2024-April 2025

This report describes a multicenter case-control investigation that found nirsevimab was 80% effective at preventing RSV-associated ICU admissions among infants.

Comments are closed here.